Pimitespib - Taiho Pharmaceutical
Alternative Names: Jeselhy; TAS 116Latest Information Update: 23 Aug 2024
At a glance
- Originator Taiho Pharmaceutical
- Class Antineoplastics; Benzamides; Imidazoles; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Gastrointestinal stromal tumours
- Phase II Prostate cancer
- Phase I Solid tumours
Most Recent Events
- 23 Aug 2024 Pimitespib is still in phase I trials for Solid tumours in USA and Italy (Otsuka Pharmaceuticals pipeline, August 2024)
- 28 Jun 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in Japan (PO)
- 28 Jun 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Italy (PO)